XXXX treatment for @entity573 refractory to initial and additional intravenous immunoglobulin.

@entity1 @entity573 @entity205 @entity453 @entity943 @entity221 @entity4144 @entity1851
BACKGROUND: There are still no definite treatments for refractory @entity573 ( @entity573 ). In this pilot study, we evaluated the use of @entity205 (CyA) treatment in @entity1 with refractory @entity573 . METHODS: We prospectively collected clinical data of CyA treatment (4-8 mg/kg/d, oral administration) for refractory @entity573 @entity1 using the same protocol among several hospitals. @entity573 is defined as the persistence or recurrence of @entity221 (37.5  C or more of an axillary temperature) at the end of the second intravenous immunoglobulin (2 g/kg) following the initial one. RESULTS: Subjects were enrolled out of 329 @entity573 @entity1 who were admitted to our 8 hospitals between January 2008 and June 2010. Among a total of 28 @entity1 of refractory @entity573 treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased @entity1851 levels, the other 4 became afebrile within 4 to 5 days. However, 6 @entity1 (21.4%) failed to become afebrile within 5 days after the start of CyA and/or high @entity221 returned after becoming afebrile within 5 days. Although @entity4144 developed in 9 @entity1 at 3 to 7 days after the start of CyA treatment, there were no serious adverse effects such as @entity943 . Four @entity1 (1.2%), 2 before and the other 2 after the start of CyA treatment, developed @entity453 . CONCLUSION: CyA treatment is considered safe and well tolerated, and a promising option for @entity1 with refractory @entity573 . Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.
